相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer
Neil E. Bhola et al.
CANCER RESEARCH (2015)
TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis
A. R. Cyr et al.
ONCOGENE (2015)
PROGgeneV2: enhancements on the existing database
Chirayu Pankaj Goswami et al.
BMC CANCER (2014)
Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight
Suzanne A. W. Fuqua et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Sumoylation Pathway Is Required to Maintain the Basal Breast Cancer Subtype
Maria V. Bogachek et al.
CANCER CELL (2014)
Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
Rinath Jeselsohn et al.
CLINICAL CANCER RESEARCH (2014)
Delineation of a FOXA1/ERα/AGR2 Regulatory Loop That Is Dysregulated in Endocrine Therapy-Resistant Breast Cancer
Tricia M. Wright et al.
MOLECULAR CANCER RESEARCH (2014)
Genome-wide activity of unliganded estrogen receptor-α in breast cancer cells
Livia Caizzi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Expression of the RET Proto-oncogene Is Regulated by TFAP2C in Breast Cancer Independent of the Estrogen Receptor
Philip M. Spanheimer et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis
Colin Clarke et al.
CARCINOGENESIS (2013)
Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker
Dennis C. Sgroi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy et al.
NATURE GENETICS (2013)
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Dan R. Robinson et al.
NATURE GENETICS (2013)
PLK1 Signaling in Breast Cancer Cells Cooperates with Estrogen Receptor-Dependent Gene Transcription
Michael Wierer et al.
CELL REPORTS (2013)
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers
Giampaolo Bianchini et al.
BREAST CANCER RESEARCH (2013)
FOXA1 is an independent prognostic marker for ER-positive breast cancer
Rutika J. Mehta et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Histone Demethylase KDM5B Collaborates with TFAP2C and Myc To Repress the Cell Cycle Inhibitor p21cip (CDKN1A)
Ping-Pui Wong et al.
MOLECULAR AND CELLULAR BIOLOGY (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer
Hany Onsy Habashy et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
AP-2γ regulates oestrogen receptor-mediated long-range chromatin interaction and gene transcription
Si Kee Tan et al.
EMBO JOURNAL (2011)
FOXA1 is a key determinant of estrogen receptor function and endocrine response
Antoni Hurtado et al.
NATURE GENETICS (2011)
PBX1 Genomic Pioneer Function Drives ERα Signaling Underlying Progression in Breast Cancer
Luca Magnani et al.
PLOS GENETICS (2011)
Subcellular Localization of Activated AKT in Estrogen Receptor- and Progesterone Receptor-Expressing Breast Cancers Potential Clinical Implications
Sunil Badve et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Estrogen-Dependent and Estrogen-Independent Mechanisms Contribute to AIB1-Mediated Tumor Formation
Maria I. Torres-Arzayus et al.
CANCER RESEARCH (2010)
Identification of Primary Gene Targets of TFAP2C in Hormone Responsive Breast Carcinoma Cells
George W. Woodfield et al.
GENES CHROMOSOMES & CANCER (2010)
FOXA1 in breast cancer
Harikrishna Nakshatri et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2009)
Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival
J. M. W. Gee et al.
JOURNAL OF PATHOLOGY (2009)
Biological determinants of endocrine resistance in breast cancer
Elizabeth A. Musgrove et al.
NATURE REVIEWS CANCER (2009)
Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer
Yuri Nikolsky et al.
CANCER RESEARCH (2008)
The humoral immune system has a key prognostic impact in node-negative breast cancer
Marcus Schmidt et al.
CANCER RESEARCH (2008)
Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance
Hany Onsy Habashy et al.
EUROPEAN JOURNAL OF CANCER (2008)
Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas
Bing Wei et al.
HUMAN PATHOLOGY (2008)
Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen
Antoni Hurtado et al.
NATURE (2008)
Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis
M. A. Thorat et al.
JOURNAL OF CLINICAL PATHOLOGY (2008)
Wwox and Ap2γ expression levels predict tamoxifen response
Gulnur Guler et al.
CLINICAL CANCER RESEARCH (2007)
Identification of estrogen-responsive genes involved in breast cancer metastases to the bone
Jun Wang et al.
CLINICAL & EXPERIMENTAL METASTASIS (2007)
FOXA1 expression in breast cancer - Correlation with luminal subtype A and survival
Sunil Badve et al.
CLINICAL CANCER RESEARCH (2007)
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade
Sherene Loi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
Lisa M. McShane et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Phosphorylation of ERα at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERα phosphorylation in breast cancer progression
N. Sarwar et al.
ENDOCRINE-RELATED CANCER (2006)
CITED1 homozygous null mice display aberrant pubertal mammary ductal morphogenesis
J Howlin et al.
ONCOGENE (2006)
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival
LD Miller et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
LM McShane et al.
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY (2005)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
LM McShane et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2005)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
LM McShane et al.
NATURE CLINICAL PRACTICE UROLOGY (2005)
Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1
JS Carroll et al.
CELL (2005)
Dual role of AP-2γ in ErbB-2-induced mammary tumorigenesis
R Jäger et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Distinct spatial expression patterns of AP-2alpha and AP-2gamma in non-neoplastic human breast and breast cancer
N Friedrichs et al.
MODERN PATHOLOGY (2005)
Activator protein-2γ (AP-2γ) expression is specifically induced by oestrogens through binding of the oestrogen receptor to a canonical element within the 5′-untranslated region
F Orso et al.
BIOCHEMICAL JOURNAL (2004)
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer
CK Osborne et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Selective coactivation of estrogen-dependent transcription by CITED1 CBP/p300-binding protein
T Yahata et al.
GENES & DEVELOPMENT (2001)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women:: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study
J Bonneterre et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
